Esophageal Cancer

Clinical Trials

Mayo Clinic has several ongoing clinical trials investigating the use of chemotherapy, concurrent preoperative and postoperative chemoradiation and other novel therapies for cancer. These clinical trials include testing new strategies and new medications with the goals of either making surgery more successful, improving outcomes in patients with no surgical options, or allowing cancer treatment in general to be better tolerated.

Below is a list of Esophageal Cancer clinical trials from the clinical trials database at Mayo Clinic.

Mayo's clinical trials include experimental treatments, often unavailable elsewhere, which frequently lead to improved patient care for people worldwide. Patients should ask their doctor at Mayo about clinical trials appropriate for their situation.

A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer (IRB #: 10-000583, 14T-MC-JVBT, NCT01246960)
Patients are being asked to take part in this research study because they have been diagnosed with esophageal, gastroesophageal junction, or stomach cancer. This study is being done to see whether ramucirumab can slow tumor growth in people with advanced adenocarcinoma of the esophagus, gastroesophageal junction, or stomach.
Read more

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
OBJECTIVES: Primary - Assess and compare the pathologic complete response rate of sequential docetaxel, oxaliplatin, and capecitabine followed by fluorouracil, oxaliplatin, and radiotherapy versus fluorouracil, oxaliplatin, and radiotherapy alone in patients with potentially resectable advanced adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia.
Read more

Endoscopic Therapy of Early Cancer in Barretts Esophagus
Participant visit requirements: Screening visit which will last 1 - 2 days, if assigned to photodynamic therapy, there will be a 3 day visit for treatment. Participants must return for a 1 day visit every three months for one year.
Read more

Familial Barrett's Esophagus
This research study is trying to determine whether Barrett's esophagus and associated esophageal cancers, specifically esophageal adenocarcinoma are inherited in certain families. Persons who are affected with Barrett's esophagus or esophageal cancer (adenocarcinoma type) are asked to complete a questionnaire that determines their habits and asks a detailed family history.
Read more

Familial Barrett's Esophagus Study
A group of doctors and scientists at the Mayo Clinic in Rochester, Minnesota, along with doctors from many other medical centers throughout the US, are working together to advance our understanding of Barrett's esophagus and esophagus cancer.
Read more

Gene Analysis for the Understanding of Barrett's Esophagus and Esophagus Cancer
This study is being done to advance the understanding of how esophagus cancer and Barrett's Esophagus develop as well as ways to treat these conditions. This will be done by analyzing blood and tissue to identify genes that may be involved in the development of esophagus cancer and Barrett's Esophagus.
Read more

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
OBJECTIVES: Primary - To evaluate the progression-free survival of patients with metastatic esophageal or gastroesophageal junction cancer treated with paclitaxel with versus without cixutumumab as second-line therapy. Secondary - To evaluate the overall survival of patients treated with these regimens.
Read more

Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
OBJECTIVES: Primary - To determine the pathologic complete response rate in patients with newly diagnosed, locally advanced adenocarcinoma of the distal esophagus or gastroesophageal junction treated with neoadjuvant panitumumab and combination chemoradiotherapy followed by surgery.
Read more

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
OBJECTIVES: Primary - To determine whether trastuzumab increases disease-free survival when combined with radiotherapy, paclitaxel, and carboplatin followed by surgery in patients with HER2-overexpressing esophageal adenocarcinoma. Secondary - To evaluate whether the addition of trastuzumab to this neoadjuvant chemoradiation increases the pathologic complete response rate and overall survival of these patients.
Read more

Varenicline and Bupropion for Smoking Cessation
Cigarette smoking is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States and accounts for 30% of U.S. cancer deaths. Varenicline and bupropion SR (sustained-release) are non nicotine pharmacotherapies FDA-indicated for the treatment of tobacco dependence in cigarette smokers.
Read more